



---

## **ASX Announcement and Media Release**

**Friday 3 June, 2016**

**SciGen Ltd**

### **CHANGES IN THE BOARD**

The Board of Directors of SciGen Limited (ASX: SIE) (the “**SciGen**”) announce changes in the Board.

#### **RESIGNATION OF DR. SLAWOMIR ZIEGERT**

On 30 May 2016, Dr. Slawomir Ziegert stepped down as President of Bioton S.A. (“Bioton”), a company holding 95.57% of the Shares of SciGen, and will, by the end of June, be joining Bioton’s Supervisory Board to support the development and global operations of Bioton and its subsidiaries. In line with the change, Dr. Ziegert has resigned as the CEO, Chairman and Director of SciGen as of 1 June 2016. The Board thanks Dr. Ziegert for his peerless contribution to SciGen and wishes Dr. Ziegert well in his new role in Bioton.

#### **APPOINTMENT OF DR JAMES KIM AS CEO**

Dr Kim was appointed as Director of Business Development of SciGen on 18 April 2016. Effective 1 June 2016, Dr. Kim will replace Dr. Ziegert as CEO of SciGen. Dr. Kim’s employment agreement with Bioton allows Dr. Kim to hold any key position within the Bioton group companies, including SciGen, as deemed necessary. Dr. Kim will not be paid any remuneration by SciGen. As CEO, Dr Kim will be responsible for developing and implementing new strategic initiatives, managing the overall operations and resources of the Company, and acting as the main point of communication between the Board of Directors and the management of the Company.

Dr. James Kim, the Director of Business Development and Licensing of Bioton S.A, is a graduate from the Trinity International University, Illinois. He completed his postgraduate studies and earned his doctorate in Biochemistry from the University of Wisconsin - Madison. Dr. Kim worked with LG Life Sciences Ltd serving in functions of corporate business development, diagnostics strategy & planning and business strategy for business areas including pharmaceuticals, biologicals and in vitro diagnostics. Between 2009 and 2011 he worked for Bioneer Corporation in Korea as Team Leader for molecular diagnostics technical support and Senior Scientist and Manager for the development of molecular diagnostics-based service platforms.

## About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes therapeutics such as rhuman Growth Hormone, rhuman Insulin and GCSF.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, China and Philippines, distribution channels in China, India, Malaysia, Myanmar, Pakistan, Thailand and Indonesia and a contract manufacturer in Poland, Bioton S.A.

<b>For further information:</b> Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: <a href="mailto:gdunlop@scigen.com.au">gdunlop@scigen.com.au</a>	James Kim CEO SciGen Ltd +65 6779 6638